Actively Recruiting
Evaluation of the ALPCO Calprotectin CLIA Assay for Measuring Calprotectin Levels in Stool to Aid Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome
Led by American Laboratory Products Company · Updated on 2026-10-30
1000
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the ALPCO Calprotectin CLIA test, an in vitro diagnostic tool that measures calprotectin protein levels in stool samples. Calprotectin is a marker of inflammation in the gut, which helps distinguish Inflammatory Bowel Disease IBD, including Crohns Disease and Ulcerative Colitis, from Irritable Bowel Syndrome IBS. The studys purpose is to confirm how well this test predicts positive and negative results in patients showing symptoms of IBS or IBD. Participants include adults with suspected IBD or IBS who provide stool samples for calprotectin measurement before or shortly after colonoscopy. The study will compare calprotectin levels measured by the ALPCO test with diagnoses confirmed through colonoscopy and histology. The test uses proposed cut-off values such as 50 gg to indicate inflammation presence, guiding whether further invasive testing is needed. During the study, patients will provide stool samples and undergo colonoscopy or have recent colonoscopy results reviewed. Samples will be frozen and later tested to measure calprotectin levels. Researchers will analyze the agreement between the test results and clinical diagnosis to assess the tests sensitivity and specificity. The primary outcome is the diagnostic value of calprotectin measurement, tracked up to 52 weeks, with participation lasting until study completion around the end of 2026.
CONDITIONS
Brief Title
ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
Research Team
Y
Yomi Ojutalayo
J
Jim Richard
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here